Industry Relations Committee (IRC)

The Industry Relations Committee (IRC) is a subcommittee of the Membership Council and serves to develop the partnership between OSHP’s pharmacist-members and its pharmaceutical industry partner-members. The IRC is responsible for continuing to enhance program development which benefit business practices for all. OSHP acknowledges that its continuing education programming could not be delivered if it were not for the assistance of our industry partners. The IRC has also instituted programming at past Annual Seminars which provided an overview of the PhRMA Code on Interactions with Healthcare Professionals, explored company participation with healthcare provider understanding of the Codes, and how pharmacy leaders involved in formulary management can build and maintain opportunities for partnering relationships.

IRC Meetings

IRC meetings are typically held bi-monthly at 8:15 AM. Students, residents, pharmacists, faculty, and industry partners are invited to attend. If you are interested in becoming involved with the IRC, please contact the Committee Liaison! Click here to view upcoming meetings.

2023-2024 IRC Chair: Andrew Gibler, Oregon Health Authority

A huge thank you to our 2023 Seminar exhibitors!

2023 Annual Seminar

Company	First	Last	Email
Octapharma	Gina	McBride	[email protected]
Xellia Pharmaceuticals	Chris	Hoffman	[email protected]
Helmer Scientific	Beth	Keck	[email protected]
Merck	Kristin	Smith	[email protected]
Oregon Board of Pharmacy	Joe	Schnabel	[email protected]
OSU - College of Pharmacy	Stacey	Olstad	[email protected]
Pacific University School of Pharmacy	Sandy	Hess	[email protected]
Salix Pharmaceuticals	Michele Dahan	Calvanese	[email protected]
DYNAVAX	Chris	Shepherd	[email protected]
GlaxoSmithKline Oncology	Kevin	Watson	[email protected]
argenx	Kristina	Knudtson	[email protected]
Janssen Pharmaceuticals, Inc.	Steve	Kuhn	[email protected]
Pfizer	Darci	Aeder	[email protected]
AstraZeneca Pharmaceuticals	James	Hawthorne	[email protected]
Seagen	Jessica	Fichtel	[email protected]
Boehringer Ingelheim Pharmaceuticals, Inc.	Amy	Burns	[email protected]
Takeda Pharmaceuticals	Amy	LoTurco	[email protected]
Grifols	David	White	[email protected]
Sandoz	Laura	Dey	[email protected]
Astellas	Kimberly	Rudkin	[email protected]
Sanofi	Gabe	Raszka	[email protected]
Regeneron	Jim	Spencer	[email protected]
Eisai Pharmaceuticals	David	Waldron	[email protected]
Pfizer Hematology	Pat	Corcoran	[email protected]
AMGEN	Jason	Matthews	[email protected]
Novo Nordisk	Marvin	Walworth	[email protected]
AstraZeneca	Danielle	Marden	[email protected]
AstraZeneca	Brigitte	Ogard	[email protected]
Novo Nordisk	Timothy	Ihle	[email protected]
Fresenius Kabi USA, LLC	Sherri	Metzger-Nenadov	[email protected]
Abbvie	Kirsten	Squitieri	[email protected]
Alnylam Pharmaceuticals	Kevin	Anderson	[email protected]
Ferring Pharmaceuticals Inc	Bradley	Howell	[email protected]
Novartis	Timothy	Polacek	[email protected]
Pacira Biosciences	Maurice	Rodrgiguez	[email protected]
Puma Biotechnology	Karin	Dunn	[email protected]
Bayer Pharmaceuticals	Jason	Witcher	[email protected]
Eli Lilly and Company	Corrie	Edwards	[email protected]
Gilead	Angela	Witkin	[email protected]
GSK	Lynn	Elmer	[email protected]
Exelixis	Douglas	Davidson	[email protected]
Genentech	Phil	Sholian	[email protected]
Alkermes	Pilar	Vigil	[email protected]
Pfizer, Inc.	Alan	Anderson	[email protected]
Takeda	James	Shelton	[email protected]

2022 Fall Seminar

Company	First	Last	Email
Alexion Pharmaceuticals/ AstraZena Pharmaceuticals	James	Hawthorne	[email protected]
Amgen Oncology	Rebecca	Kapanoske	[email protected]
argenx	Tricia	Beeler	[email protected]
Astellas	Kimberly	Rudkin	[email protected]
Bayer Pharmaceuticals	Jason	Witcher	[email protected]
Boehringer Ingelheim	Amy	Burns	[email protected]
Bristol-Myers Squibb	Oliver	Johnson	[email protected]
Chiesi	Sarah	Lutz	[email protected]
Fresenius Kabi USA, LLC	Chris	Colihan	[email protected]
Genentech BioOncology	Phil	Sholian	[email protected]
Janssen	David	Johnson	[email protected]
Merck	Scott	Sears	[email protected]
Novartis	Timothy	Polacek	[email protected]
Novo Nordisk - Obesity	Marvin	Walworth	[email protected]
Novo Nordisk - Diabetes	Timothy	Ihle	[email protected]
Octapharma	Gina	McBride	[email protected]
Oregon Board of Pharmacy	Joe	Schnabel	[email protected]
Oregon State University College of Pharmacy	Sharon	Rask	[email protected]
Pacific University Oregon - School of Pharmacy	Sandy	Hess	[email protected]
Pfizer Hematology	Pat	Corcoran	[email protected]
Pfizer Inc.	Lucas	dePinna	[email protected]
Propel Health	Amy	Speakman	[email protected]
Puma Biotechnology	Thomas	Carague	[email protected]
Regeneron	Shelby	McQueen	[email protected]
Sanofi	Andrea	Seeley	[email protected]
Seagen	Mickey	Jaca	[email protected]
Sobi	David	Murray	[email protected]
Takeda Pharmaceuticals	Andrea	Seeley	[email protected]